Darinaparsin - Solasia Pharma
Alternative Names: Darvias; SP-02; SP-02L; Zinapar; ZIO-101Latest Information Update: 14 Jun 2024
At a glance
- Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
- Developer Nippon Kayaku; Solasia Pharma; ZIOPHARM Oncology
- Class Amines; Antineoplastics; Arsenicals; Oligopeptides; Pentanoic acids; Small molecules; Sulfides
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Peripheral T-cell lymphoma
- Discontinued Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 14 Jun 2024 Phase-II clinical trials in Peripheral T-cell lymphoma in China (IV), prior to June 2024 (Solasia Pharma pipeline, June 2024)
- 14 Jun 2024 Phase-II clinical trials in Peripheral T-cell lymphoma in Europe (IV), prior to June 2024 (Solasia Pharma pipeline, June 2024)
- 14 Jun 2024 Solasia Pharma files for regulatory approval for Peripheral T-cell lymphoma in Colombia, prior to June 2024 (Solasia Pharma pipeline, June 2024)